List of Excipients in Branded Drug ADLARITY

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Corium LLC	ADLARITY	donepezil hydrochloride	65038-055	ASCORBYL PALMITATE
Corium LLC	ADLARITY	donepezil hydrochloride	65038-055	CROSPOVIDONE
Corium LLC	ADLARITY	donepezil hydrochloride	65038-055	GLYCERIN
Corium LLC	ADLARITY	donepezil hydrochloride	65038-055	LAURYL LACTATE
Corium LLC	ADLARITY	donepezil hydrochloride	65038-055	SODIUM BICARBONATE
Corium LLC	ADLARITY	donepezil hydrochloride	65038-055	SORBITAN MONOLAURATE

ADLARITY Excipient Strategy and Commercial Opportunities

Last updated: August 5, 2026

ADLARITY is a once-weekly donepezil transdermal system approved by the FDA in 2022 for mild, moderate, and severe dementia of the Alzheimer’s type. Its commercial differentiation depends less on the active ingredient than on the excipient-controlled delivery system: pressure-sensitive adhesives, skin permeation, seven-day drug release, patch adhesion, and tolerability. The main commercial opportunity is to improve transdermal performance without compromising adhesion, skin safety, manufacturing consistency, or regulatory comparability.

What is ADLARITY and how does its formulation work?

ADLARITY contains donepezil and delivers a continuous nominal dose of either 5 mg/day or 10 mg/day through the skin for seven days. The product is manufactured by Corium, Inc. and is supplied as a transdermal system rather than an oral tablet or capsule. The FDA approved ADLARITY under NDA 214365 in June 2022. (FDA, 2022a)

The formulation is a drug-in-adhesive patch. Donepezil is incorporated into an adhesive matrix that contacts the skin. The system also includes a backing layer and a removable release liner. The adhesive layer must perform several functions simultaneously:

Functional requirement	Excipient or component role
Maintain skin contact for seven days	Pressure-sensitive adhesive
Control donepezil release	Adhesive matrix and polymer structure
Support skin permeation	Vehicle, polymer, and permeation-control design
Prevent dose loss	Backing layer and matrix integrity
Protect the adhesive before use	Release liner
Limit irritation	Adhesive selection and impurity control
Support manufacturing	Coating, drying, lamination, and die-cutting properties

ADLARITY’s formulation strategy addresses a major limitation of oral donepezil: gastrointestinal exposure and the need for daily dosing. The patch is replaced once weekly, which can reduce daily administration burden and may help caregivers manage treatment. The label warns that transdermal delivery can produce skin reactions, making adhesive and excipient performance commercially important. (DailyMed, 2024)

Which excipients are used in the ADLARITY patch?

The commercially relevant excipient categories are the adhesive matrix, permeation-control components, backing materials, and release-liner materials. Public FDA labeling describes the product as a transdermal system but does not provide the same detailed quantitative excipient disclosure typically found in an oral tablet label. The formulation is therefore best analyzed by function rather than by assuming a conventional inactive-ingredient list.

Pressure-sensitive adhesive

The adhesive is the central excipient platform. It must remain tacky during the full seven-day wear period while avoiding excessive residue, edge lift, and skin stripping during removal.

Potential adhesive classes include acrylic, silicone, and rubber-based systems. Each creates a different risk and opportunity profile:

Adhesive class	Advantages	Principal risks
Acrylic	Broad formulation flexibility, strong cohesion, tunable drug solubility	Irritation, residual monomer, variable drug crystallization
Silicone	High skin compatibility and reliable repositioning	Lower drug-loading capacity for some molecules, higher cost
Rubber-based	Strong tack and low raw-material cost	Oxidative instability, extractables, odor, aging risk

A follow-on product cannot assume that replacing one adhesive with another is a minor formulation change. The adhesive affects drug solubility, diffusion, crystallization, skin flux, residual drug, adhesion, peel force, and irritation. For an ANDA or 505(b)(2) applicant, adhesive substitution can create a substantial equivalence and clinical-bridging burden.

Permeation-control excipients

Donepezil is a lipophilic small molecule with established oral pharmacology. Transdermal delivery still requires control of partitioning between the adhesive matrix, stratum corneum, viable epidermis, and systemic circulation.

Relevant excipient strategies include:

• Solubilizers that maintain donepezil in a noncrystalline state.
• Plasticizers that change polymer mobility and drug diffusion.
• Fatty acids or fatty alcohols that alter skin partitioning.
• Terpenes or related permeation enhancers.
• Polyols or other co-solvents that modify drug activity.
• Polymer blends that regulate release and adhesion.

Permeation enhancers create a direct tradeoff. Increasing skin flux can reduce patch size, but it can also increase erythema, edema, itching, or sensitization. The strongest commercial formulation is not necessarily the one with the highest in vitro permeation rate. It is the one that maintains therapeutic exposure with acceptable skin tolerability over repeated weekly use.

Backing layer and release liner

The backing layer protects the matrix from water, friction, and drug loss. It can influence occlusion, temperature at the skin surface, mechanical flexibility, and dose stability.

The release liner must be removed cleanly without pulling adhesive away from the matrix. Its release force must remain consistent during storage. Liner variation can produce dosing and manufacturing problems even when the drug-in-adhesive chemistry remains unchanged.

What formulation attributes create commercial opportunities for ADLARITY?

The most valuable opportunities are improvements that preserve the weekly dosing concept while reducing failure modes.

Improved skin tolerability

The product label includes warnings for application-site reactions. Skin tolerability is a major commercial variable because repeated irritation can cause discontinuation or poor adherence. Formulation opportunities include:

• Lower-irritancy adhesive chemistry.
• Reduced residual monomer and oligomer levels.
• Lower concentrations of aggressive permeation enhancers.
• A breathable backing film.
• Reduced occlusion.
• More predictable removal force.
• Improved control of adhesive aging.

A competitor that matches systemic exposure while lowering the frequency or severity of skin reactions could obtain meaningful differentiation.

More reliable seven-day adhesion

Weekly wear creates a demanding adhesion profile. The patch must withstand bathing, sweating, clothing friction, and movement. Commercial development can focus on:

• Better edge adhesion.
• Lower curl and lift.
• Reduced cold-flow and residue.
• Improved adhesion across elderly skin types.
• Greater resistance to humidity and temperature variation.
• More consistent adhesion after application to different anatomical sites.

A product that requires fewer replacement interventions may have a practical advantage even if its pharmacokinetic profile is similar.

Smaller patch size

A smaller patch can improve patient acceptance, concealment, and adherence. Size reduction requires higher drug loading, higher skin flux, or both. Those changes can increase crystallization, irritation, and dose variability.

The commercial value of size reduction must be measured against:

• Delivered dose over seven days.
• Skin reaction rates.
• Residual drug at removal.
• Patch adhesion.
• Manufacturing yield.
• Packaging and shipping costs.

Flexible dose delivery

ADLARITY currently offers 5-mg/day and 10-mg/day systems. Future products could explore intermediate strengths, dose titration systems, or controlled-release platforms that reduce the need to switch between patch strengths.

A dose-flexible product may be attractive in populations where tolerability limits rapid escalation. A multi-strength portfolio also creates opportunities for payer contracting and pharmacy substitution controls, subject to regulatory approval.

What patents protect ADLARITY and its excipient strategy?

ADLARITY protection is likely to include a combination of formulation, transdermal delivery, dosing, and manufacturing claims. The commercial value of the estate depends on whether claims cover the specific adhesive matrix and release profile or merely broad use of donepezil in a patch.

Relevant claim categories include:

Patent category	Potential protected subject matter	Competitive relevance
Composition	Donepezil combined with a particular adhesive or polymer system	Can block adhesive substitution
Transdermal system	Patch architecture, backing layer, matrix, and liner	May cover commercial product configuration
Release profile	Seven-day delivery, flux range, or residual drug limits	Can constrain design-around options
Method of use	Treating Alzheimer’s dementia with a donepezil patch	May affect labeling strategy
Manufacturing	Coating, drying, lamination, or crystallization control	Can raise process-transfer costs
Packaging	Stability protection and moisture control	Usually secondary but commercially relevant

The FDA Orange Book is the controlling public source for listed patents and regulatory exclusivity associated with an approved small-molecule drug. A patent-by-patent freedom-to-operate analysis should distinguish listed patents from unlisted formulation, process, and foreign rights. (FDA, 2024)

How strong is the ADLARITY patent estate?

The estate is strongest where three conditions overlap:

1. The claims cover a drug-in-adhesive system rather than a generic patch concept.
2. The claims include measurable release, adhesion, or skin-flux limitations.
3. The commercial formulation practices those limitations in a way that is difficult to replicate with a different adhesive.

The estate is weaker if competitors can achieve equivalent exposure with a different adhesive class, different enhancer system, or different patch architecture without practicing the asserted claims.

Transdermal patents often create more design-around paths than composition-of-matter patents. A generic manufacturer may pursue a different polymer, alternate permeation enhancer, altered patch area, or modified coating process. The success of that strategy depends on whether the FDA requires clinical bridging or accepts a comparative in vitro and pharmacokinetic package.

When does ADLARITY lose regulatory exclusivity?

ADLARITY is a reformulated dosage form of donepezil, an established active ingredient. It therefore does not receive the five-year new chemical entity exclusivity associated with a new active moiety.

The likely regulatory framework is:

Protection type	ADLARITY position
New chemical entity exclusivity	Not applicable because donepezil was previously approved
Three-year clinical-investigation exclusivity	Associated with approval of the new transdermal dosage form and supporting clinical work
Orphan-drug exclusivity	Not applicable based on the approved Alzheimer’s dementia indication
Pediatric exclusivity	Applies only if separately granted
Patent protection	Depends on current Orange Book listings and other enforceable rights

The three-year exclusivity period began with the June 2022 approval and generally would block approval of an ANDA or 505(b)(2) relying on the same changed dosage form until approximately June 2025, subject to the scope of the exclusivity and FDA determinations. It does not prevent all independent applications or all forms of competition. (FDA, 2022a; FDA, 2024)

Patent expiration dates must be taken from the current Orange Book entry and relevant patent records. Regulatory exclusivity and patent expiry are separate barriers. A product can lose three-year exclusivity while remaining protected by patents.

What is the Orange Book status of ADLARITY?

ADLARITY is a prescription drug approved under an NDA and is eligible for Orange Book patent listing. The Orange Book is the relevant source for:

• Listed patents.
• Patent-use codes.
• Patent expiration information.
• Therapeutic-equivalence evaluations.
• Approved dosage form and route.
• Generic application status where publicly available.

The key Orange Book issue is whether listed method-of-use patents cover the approved Alzheimer’s indication and whether formulation patents cover the transdermal system itself. A generic applicant may challenge listed patents through a Paragraph IV certification or may file a Paragraph III certification that delays approval until patent expiry.

The absence of a publicly visible generic launch does not establish that the product has no challengers. Patent certifications, litigation, settlements, and tentative approvals can change over time. (FDA, 2024)

Which companies are most likely to challenge ADLARITY?

The likely challengers are companies with:

• Existing transdermal manufacturing capacity.
• Experience with ANDA or 505(b)(2) submissions.
• Access to adhesive and coating technology.
• Commercial portfolios in neurology or geriatric care.
• Ability to conduct comparative pharmacokinetic and adhesion studies.

Potential competitive groups include large generic manufacturers, specialty generic companies, and transdermal contract development and manufacturing organizations. A conventional oral donepezil manufacturer is not automatically positioned to compete because the primary technical barrier is patch manufacturing rather than active-ingredient sourcing.

Generic entry risks

The principal generic-entry risks are:

• A Paragraph IV challenge to formulation or method patents.
• A 505(b)(2) product with a different patch architecture.
• A lower-cost patch using an alternative adhesive.
• A product with equivalent exposure but improved adhesion.
• An authorized generic or license arrangement.
• A companion product using oral donepezil for patients unwilling to use a patch.

A generic patch may face higher development costs than an oral generic because it must demonstrate consistent adhesion, dose delivery, skin tolerability, residual drug control, and manufacturing reproducibility.

What formulation patents and manufacturing barriers matter most?

The strongest practical barriers may be process-related rather than purely chemical. A transdermal system requires control of:

• Drug dispersion in the adhesive.
• Coating thickness.
• Drying temperature and solvent removal.
• Web speed and coating uniformity.
• Lamination pressure.
• Die-cutting dimensions.
• Residual solvent.
• Drug crystallization during shelf life.
• Patch-to-patch dose uniformity.
• Adhesive aging.

A formulation that performs well in a laboratory hand-cast film may fail at commercial scale. Coating defects, edge effects, migration into the backing layer, and changes in adhesive rheology can create batch failures.

Manufacturing know-how can therefore support commercial exclusivity even when a competitor designs around the patent claims. Corium’s technology and process experience are commercially relevant because scale-up can determine whether a nominally equivalent transdermal formulation is economically viable.

How does ADLARITY compare with oral donepezil and competing Alzheimer’s drugs?

Product	Active ingredient	Delivery	Dosing frequency	Main commercial advantage	Main limitation
ADLARITY	Donepezil	Transdermal	Weekly	Reduced administration frequency	Skin reactions and patch adherence
Oral donepezil tablets	Donepezil	Oral	Daily	Low-cost, established generic supply	Daily dosing and gastrointestinal effects
Donepezil orally disintegrating tablet	Donepezil	Oral	Daily	Administration without swallowing a conventional tablet	Still requires daily dosing
Rivastigmine patch	Rivastigmine	Transdermal	Daily	Established transdermal precedent	Daily replacement and skin tolerability
Memantine products	Memantine	Oral or extended-release oral	Daily	Different pharmacologic option	Not a direct delivery substitute
Anti-amyloid antibodies	Various biologics	Intravenous or other clinical administration	Periodic	Disease-modifying treatment pathway	High cost, monitoring, infusion or administration burden

ADLARITY’s direct competition is oral generic donepezil, not only other branded Alzheimer’s therapies. The patch must justify its premium through adherence, caregiver convenience, tolerability, or persistence with therapy.

What licensing deals and partnership opportunities exist?

The most attractive licensing opportunities involve enabling technologies rather than the active ingredient. Candidate deal areas include:

Adhesive and permeation technology

A company with a low-irritancy adhesive, enhanced skin flux, or long-wear platform could license technology to an ADLARITY competitor or pursue a co-development transaction with a neurology-focused commercial partner.

Manufacturing partnerships

Transdermal CDMOs can create value by offering:

• Solvent or solvent-free coating.
• High-throughput web handling.
• Adhesive matrix scale-up.
• Analytical methods for drug distribution.
• Stability and packaging qualification.
• Commercial patch converting.

Regional commercialization

ADLARITY’s weekly administration may have value in markets with large caregiver populations and limited nursing support. Regional partners could support registration, reimbursement, and distribution in Europe, Japan, China, South Korea, and selected emerging markets. Foreign patent and regulatory rights must be evaluated separately from U.S. rights.

Combination and adherence programs

Commercial partnerships could pair the patch with:

• Caregiver medication-management services.
• Pharmacy refill programs.
• Adherence monitoring.
• Home-health channels.
• Long-term-care procurement.
• Digital reminders and replacement schedules.

These arrangements are more likely to improve market access than to create exclusivity, but they can increase persistence and reduce switching to oral generics.

What is the revenue exposure to generic entry?

ADLARITY’s revenue exposure depends on whether it captures patients who would otherwise use low-cost oral donepezil or patients who discontinue oral therapy. The second group provides stronger differentiation.

Key revenue variables include:

Variable	Commercial effect
Share of oral donepezil patients converted to the patch	Determines addressable substitution market
Net price premium	Determines revenue durability after exclusivity
Skin discontinuation rate	Reduces persistence and refill volume
Caregiver and long-term-care adoption	Can support higher adherence
Insurance coverage	Determines access against generic oral alternatives
Generic patch timing	Creates direct price competition
Product-line extensions	Can defend revenue after initial exclusivity

A generic oral challenger already limits pricing power because donepezil tablets are widely available. A generic transdermal challenger would create a more direct threat, particularly if it demonstrates comparable exposure and lower acquisition cost.

What generic launch scenarios exist for ADLARITY?

Scenario 1: No early patent challenge

The product retains a branded position until listed patents expire or a settlement permits later entry. Corium can focus on adherence, caregiver use, and reimbursement.

Scenario 2: Paragraph IV litigation

A generic applicant challenges one or more listed patents. Litigation may delay approval, create a 30-month stay where applicable, or result in a settlement with a negotiated launch date. The commercial outcome depends on claim scope, patent validity, and the generic’s ability to maintain a technically distinct formulation.

Scenario 3: 505(b)(2) alternative patch

A sponsor develops a different donepezil patch and relies partly on existing FDA findings. This route may avoid some ANDA constraints but can require additional clinical or pharmacokinetic evidence.

Scenario 4: Authorized generic or licensed alternative

The rights holder licenses a second manufacturer or launches an authorized generic. This can capture price-sensitive demand while preserving some branded economics.

Scenario 5: Oral generic substitution

Pharmacies and payers continue shifting patients to generic oral donepezil. This is the most persistent competitive threat because it does not require a transdermal competitor.

Key Takeaways

• ADLARITY’s core value is its weekly transdermal delivery system, not the donepezil molecule.
• The adhesive matrix is the most important excipient-controlled component.
• Commercially valuable improvements include lower irritation, stronger seven-day adhesion, smaller patch size, and better dose consistency.
• ADLARITY is a small-molecule product and faces generic, not biosimilar, competition.
• The three-year regulatory exclusivity period associated with the 2022 approval generally reached its expected endpoint around June 2025, while patent barriers may continue separately.
• The Orange Book is the controlling source for listed U.S. patents, use codes, and expiration information.
• Generic patch development is technically more difficult than oral donepezil development because adhesion, skin flux, crystallization, coating, and residual drug must all be controlled.
• The strongest licensing opportunities are in adhesive technology, permeation control, transdermal manufacturing, regional commercialization, and adherence services.
• Oral generic donepezil remains ADLARITY’s largest commercial substitute.

FAQs About ADLARITY Excipients and Commercial Strategy

Does ADLARITY use a reservoir patch or a drug-in-adhesive patch?

ADLARITY is described as a transdermal system containing donepezil in an adhesive matrix. It is not marketed as a conventional oral formulation or an implantable reservoir system. (DailyMed, 2024)

Can a generic manufacturer change the ADLARITY adhesive?

A generic or 505(b)(2) sponsor may seek to use a different adhesive, but the change can affect drug release, skin permeation, adhesion, irritation, and pharmacokinetics. FDA requirements will depend on the application pathway and the degree of formulation difference.

Is ADLARITY at risk from biosimilars?

No. ADLARITY contains donepezil, a chemically synthesized small molecule. Competitive products would generally use ANDA or 505(b)(2) pathways rather than the biosimilar pathway.

Can a permeation enhancer create a patentable ADLARITY alternative?

Yes. A particular enhancer, enhancer concentration, polymer combination, flux range, or release profile may support patent claims if the claims satisfy novelty, nonobviousness, written-description, and enablement requirements. Regulatory approval does not itself establish patentability.

What is the most attractive commercial improvement for a next-generation donepezil patch?

The strongest opportunity is a patch that maintains weekly systemic exposure while reducing skin reactions and improving adhesion on elderly skin. A smaller patch or lower manufacturing cost could add value, but tolerability and reliable wear are more likely to influence treatment persistence.

References

1. DailyMed. (2024). ADLARITY (donepezil transdermal system) prescribing information. U.S. National Library of Medicine.

2. U.S. Food and Drug Administration. (2022a). Approval letter: ADLARITY (donepezil transdermal system), NDA 214365. Center for Drug Evaluation and Research.

3. U.S. Food and Drug Administration. (2022b). ADLARITY prescribing information. Center for Drug Evaluation and Research.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. Center for Drug Evaluation and Research.

5. U.S. Food and Drug Administration. (2024). Regulatory information on generic drugs, patent certifications, and exclusivity. Center for Drug Evaluation and Research.